• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register

PD-184352

Product ID P1200
Cas No. 212631-79-3
Purity ≥98%
Product Unit SizeCostQuantityStock
1 mg $88.60 In stock
5 mg $129.50 In stock
25 mg $395.20 In stock
100 mg $1,226.60 In stock
Bulk Quote
Add to Wishlist

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

PD-184352 is an anticancer chemotherapeutic MEK1/2 and Raf inhibitor that is particularly effective against cancers harboring B-Raf or RAS mutations such as V600E. PD-184352 enhances p53 accumulation and caspase activation, increases levels of pro-apoptotic Bim protein, and decreasing levels of cyclin D1, inducing cell cycle arrest and apoptosis in several cancer cell lines. This compound also induces tumor regression in animal models carrying lung tumors.

Product Info

Cas No.

212631-79-3

Purity

≥98%

Formula

C17H14ClF2IN2O2

Formula Wt.

478.66

Chemical Name

2-[(2-chloro-4-iodophenyl)amino]-N-(cyclopropylmethoxy)-3,4-difluoro-benzamide

IUPAC Name

2-(2-chloro-4-iodoanilino)-N-(cyclopropylmethoxy)-3,4-difluorobenzamide

Synonym

CI-1040

Solubility

Soluble in DMSO

Appearance

White to off white powder

Shipping and Storage

Store Temp

Ambient

Ship Temp

Ambient

Downloads

MSDS

P1200 MSDS PDF

Info Sheet

P1200 Info Sheet PDF

Brochures

Ras-Raf-MEK-ERK Pathway Booklet

References

Wickenden JA, Jin H, Johnson M, et al. Colorectal cancer cells with the BRAF(V600E) mutation are addicted to the ERK1/2 pathway for growth factor-independent survival and repression of BIM. Oncogene. 2008 Dec 4;27(57):7150-61. PMID: 18806830.

Lunghi P, Giuliani N, Mazzera L, et al. Targeting MEK/MAPK signal transduction module potentiates ATO-induced apoptosis in multiple myeloma cells through multiple signaling pathways. Blood. 2008 Sep 15;112(6):2450-62. PMID: 18583568.

Bain J, Plater L, Elliott M, et al. The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315. PMID: 17850214.

Ji H, Wang Z, Perera SA, et al. Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models. Cancer Res. 2007 May 15;67(10):4933-9. PMID: 17510423.

Squires MS, Nixon PM, Cook SJ. Cell-cycle arrest by PD184352 requires inhibition of extracellular signal-regulated kinases (ERK) 1/2 but not ERK5/BMK1. Biochem J. 2002 Sep 1;366(Pt 2):673-80. PMID: 12069688.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2023 LKT Laboratories, All Rights Reserved - Products for research use only